|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM038691221 |
| 003 |
DE-627 |
| 005 |
20250127022215.0 |
| 007 |
tu |
| 008 |
231221s1985 xx ||||| 00| ||jpn c |
| 028 |
5 |
2 |
|a pubmed25n0129.xml
|
| 035 |
|
|
|a (DE-627)NLM038691221
|
| 035 |
|
|
|a (NLM)3887870
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a jpn
|
| 100 |
1 |
|
|a Okada, S
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Clinical application of PPC for nonspecific chronic prostatitis
|
| 264 |
|
1 |
|c 1985
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 19.06.1985
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a The clinical effectiveness of PPC, amino acid preparation, on nonspecific chronic prostatitis was evaluated by the double-blind test method. A mixture of two pollen extracts which has been widely employed for the treatment of chronic prostatitis was used as a control. Neither antibiotics nor anti-inflammatory drug was administered during the investigation. A total of 76 cases was reported from six facilities but 14 of them were excluded or dropped out. In 32 cases in the PPC group, subjective symptoms such as discomfort after urination, discomfort in the perineal region, pollakisuria, sense of residual urine and dysuria were improved in 50.0 approximately 61.9% and 70.0 approximately 83.3% after 2- and 4-week administrations, respectively. Similar results regarding each subjective symptom were obtained in 30 cases of the control group and there was no significant difference between the two groups. In the overall clinical effectiveness concerning subjective symptoms, the effective rate including excellently, moderately and slightly effective was 81.3% with PPC and 83.3% with control drug. However when the effective rate was limited to excellently and moderately effective, PPC was slightly superior to the control drug (50.5% versus 36.7%). In regard to prostatic tenderness by the digital examination, both PPC and control drug induced relatively good improvement after 2-week administration. The degree of improvement, however, was not increased in the subsequent 2 weeks. Sclerotic change of the prostate was poorly recovered in both groups even after 4-week treatment. Swelling of the prostate was alleviated in 12.5% of the control group after 2 weeks and in 31.8% after 4 weeks.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| 650 |
|
4 |
|a Clinical Trial
|
| 650 |
|
4 |
|a Controlled Clinical Trial
|
| 650 |
|
4 |
|a English Abstract
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Drug Combinations
|2 NLM
|
| 650 |
|
7 |
|a PPC amino acid preparation
|2 NLM
|
| 650 |
|
7 |
|a Glutamine
|2 NLM
|
| 650 |
|
7 |
|a 0RH81L854J
|2 NLM
|
| 650 |
|
7 |
|a Alanine
|2 NLM
|
| 650 |
|
7 |
|a OF5P57N2ZX
|2 NLM
|
| 650 |
|
7 |
|a Glycine
|2 NLM
|
| 650 |
|
7 |
|a TE7660XO1C
|2 NLM
|
| 700 |
1 |
|
|a Hamada, K
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Takasaki, N
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Demura, A
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Okano, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kirime, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Noda, H
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ono, S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Akita, Y
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Nishimoto, K
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Hinyokika kiyo. Acta urologica Japonica
|d 1962
|g 31(1985), 1 vom: 15. Jan., Seite 179-85
|w (DE-627)NLM012631779
|x 0018-1994
|7 nnns
|
| 773 |
1 |
8 |
|g volume:31
|g year:1985
|g number:1
|g day:15
|g month:01
|g pages:179-85
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_20
|
| 912 |
|
|
|a GBV_ILN_22
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_60
|
| 912 |
|
|
|a GBV_ILN_72
|
| 912 |
|
|
|a GBV_ILN_120
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_2001
|
| 912 |
|
|
|a GBV_ILN_2003
|
| 912 |
|
|
|a GBV_ILN_2005
|
| 912 |
|
|
|a GBV_ILN_2006
|
| 912 |
|
|
|a GBV_ILN_2008
|
| 912 |
|
|
|a GBV_ILN_2010
|
| 912 |
|
|
|a GBV_ILN_2012
|
| 912 |
|
|
|a GBV_ILN_2018
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 31
|j 1985
|e 1
|b 15
|c 01
|h 179-85
|